Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree with tootall, charts are very limited and usually leave the investor with missing out on the big picture, as most who were touting charts have found here.
Never used charts in over 30 years, fundamentals control the market not T/A, like I have said numerous times before there are a million catalyst's each day which make charting irrelevant unless you are a frequent trader.
Case in point I have held all my position from the initial buys, where others tried to meander in and out timing those charts, who would be up the most now. Those that traded in and out from the resistance points that were shown on those charts or those of us that have held our entire positions?
On investments that hold tremendous potential such as TPIV why would a better strategy be to dollar cost average...the "Buffett" scenario of investing is hard to dispute.
Long term investors over time usually do much better than trying to gauge the market by charts which are simply a guide as to what may occur. Fundamentals are a much better indicator of what proves to be the strength of a company...fundamentals do not lie.
BLU
Excellent post...you are right we are probably still $2 minimum away, and that's before they "formally" announce the start of Phase 11.
Thanks
BLU
...Weeeeeeeeeeeeee...touched $1.00
Thanks RK, and tootalljones your post's are also quite informative and right on point, looks like we will all share in the spoils together.
BLU
.9 cents away from another $10 Mill, giving them about 12 million minimum in coffers.
12 Mill cash, best science in the industry, low float, Possible Fast Track, IND, Orphan Status update, news imminent on full line data, news on completion of securing the licensing, new Collaboration update, entry into Phase 11 in at least two indications possibly more, update on Polystart.
Any of these catalyst’s may move stock into the $1.50 range, most likely will be driven into the $2/$3 range if most or all come to fruition, company will be debt free, and have the best in class for exceptional low cost to produce. Glynn hinted that they will be close to a commercial product by year end.
More than enough money now to complete Phase 11, on possibly both indications, as MAYO has already has obtained partial funding...multiple multi-billion dollar markets.
As we move into the $1.50/$2 range expect news of the up-list, which could drive us much higher, all of these drivers possible within the next 3 months.
Tapimmune’s game plan looks quite flawless at this point, positioning them for what most would expect to be multiple buyout candidates, which has been my premise from the outset.
DART most likely to put the brakes on share flow moving forward, making the rise in share price accelerated.
GLTA Fundamentals still look great.
BLU
83.376 at 10:08 down 0.049
22,936 shares at 9;52AM down 0.003
Tpizzazz...answer too your questions, as I see them.
1. First thing I learned in business, is that nothing ever happens on time and usually over budget, my take is that Glynn said they would initiate Phase 11 3rd Quarter, I have set my sites towards the latter end of 3rd Q. [See 90 day timeline I took from FDA website below]
2. As they have to finalize the licensing from mayo, sounds like they have the sites and investigators in place, I believe they were/are oversubscribed for the trial.
The FDA is a “Crazy Chicken” [Kevin Oleary’s saying, have adopted it] once again time frame cannot be determined, in this case the fact that the Mayo did the trial and was so very thorough, that should I would think bypass some of the politics moving forward. They have been very tight lipped, mainly because a lot of companies try to align themselves with the mayo without actually being so, they have been burned before.
This from the FDA website, after submission these are the stages
What happens after submission?
You will be sent a letter acknowledging receipt of the application.
Reviewed by reviewer ?designation Team Leader ?OOPD director.
Expect <90 days to decision.
A negative decision can always be readdressed.
Roughly 60-70% of applications result in granting orphan drug designation status.
3. I believe that Wednesday for the .50 warrants, think we went over on Thursday of last week, so Wed of this upcoming week, either way by weeks end. Somewhat confusing now on how many warrants will be exercised 5 or 7.3 or 10 Mill raising somewhere between 2.5 and 5 Mill dollars. [I think not sure] anyone with more clarity please chime in.
4. Then if we look at the next wave at $1.00, once again somewhere between5 and 7.3 or 10 Mill warrants [I think not sure] anyone with more clarity please chime in.
I agree I think that there will be news within next week or two expecting HER2/nue for sure and maybe news on TNBC, expecting POLYSTART news soon. Collaboration with someone, possible Grant Funding etc.
They really could post, on a number of fronts within the next 3 months I expect as I have said that the game plan is in effect...wouldn’t want to blink to long at this point. Full line of data, along with initiation of Phase 11 should really spur the market.
Patience is the key here, it looks like the turning point is finally here, their science may set a new precedent in the industry if so all bets are off, skies the limit.
5. Thinking that within the next month the will have made the application to FDA, but expect the stock to meander slowly upwards any good news out from Tapimmune. Expect stock will hold .75 plus or spur stock higher in my opinion. Would love to see in at $1.50 going into the FDA, and Phase 11 announcements.
Mostly conjecture at this point.
If I was KENNETH DART each day that passes on the OTC is one more day that the stock can be manipulated...as we feel now, after all these years no way the plan this time is not in place.
They cannot afford to mess up getting the stock price into position for the up-list, and that news I think will be monumental. They in the past 6 months have done a great job of educating the investor community, thinking that there are many on the sidelines waiting to pounce.
BLU
Big Pharma will be the ones buying us out at a very, very hefty premium...many patents ran out in 2014 for giants like Roche and Phizer, least of our worries!
Remember even the companies that may be further along in trials, their technology is complimentary to most if not all, even as we speak it is completely plausible that Tapimmune has been approached by more than 1 Big Pharma.
That is why Tapimmune is securing/finalizing the licencing deal as we speak.
BLu
A Question: What price do you put on a Vaccine/drug that has the potential to save millions of lives, is safe, and is so cost effective that anyone could afford it?
Very impressive RK, Great work!
BLU
Thank's tootalljones, I try every day, and know this company inside and out..am so hard pressed so far to find "ANY" negatives now, or potentially down the road...other than as I stated the
recurrence to disease. If and when I find something I will post for all to analyze
Edith Perez's excitement on her face, in the short video speaks volumes as she above all others knows the comparison to Herceptin, and Glynn who is a very low key individual, you can hear the muted excitement in his voice.
It is a very exciting place to be now and in the future, it may change an exponential amount of lives in the future not only medically, but to those who are believer's in Tapimmune stock.
BLU
Bio Tech stocks in comparative stages as we will be in after 3rd quarter, just as a guide to what stock could be at within 12/24 months, noticeable trend is that at some point these stocks and many others have made a major move upward at some point.
We will have 2 Phase 11, with issued Patents from Mayo which may receive Fast Track, Orphan or IND or all, Polystart entering Phase 1, Glynn hinted at a commercial viable product by year end and collaboration [unknown]
Multi Billion Dollar Markets in each indication, and possible others vaccine seems to have not only a broad approach to the indications Glynn has listed but potentially many more.
Herceptin 7 Bill per year, to be bought out for 1 Billion at even 100 Mill shares out= $10 stock will be at the very low end. Once the Up-List occurs and the real buying starts, think we will see stock price in line with some of these listed below...$15 to $20 seems to not be out of the question at all.
If the recurrence to disease remains low, as 3, 6, and 9 month timeframes are hit that is a real driver, non toxic like KITE and JUNO’s Car-T, our very low cost is massive, as a lot of the marketed drugs are 50.000/100,000 per year.
Find it very hard to find any problems to date, and possibly in the future, other than disease recurrence that is the key.
I hope that they have the game plan in place to work the up-list into the Phase 11 news, which would only put us about 3 months out...latest
Glynn has also hinted at possible Grant Funding, we will have our .50 funding, and it looks close to getting the 1.00 warrants also, cash in hand setting the scene for the up-list, Phase 11 news should get the price into 2/4 or more.
ACADIA [ACAD] Price: $39.78 52 Week HI: 46.48 Shares Out: 100,000 Mill Book: 2.84 2 Phase 11/ 1 Phase 3
IMMUNOGEN [IMGN] Price: 14.19 52 Week HI: 19.74 Shares Out: 86 Mill Book: .69 Multiple Phase 111
INOVIO [INO] Price: 8.93 52 week HI: 15,20 Shares Out: 71 Mill Book: 1.70 Cancer/Infectious Disease 1 Phase 11/Multiple Phase 1
KITE PHARMA [KITE] Price: 58.27 52 Week HI: 89.21 Shares Out: 43 MILL Book: 8.97 2 Phase 11/Multiple Phase 1
JUNO [JUNO] Price: 61.45 52 Week HI: 69.25 Shares Out: 90 Mill Book: 0 Multiple Phase 1/No Phase 11
NORTHWEST BIO [NWBO] Price: 10.07 52 Week HI: 17.90 Shares Out: 76 Mill Book: -1.01 1 Phase 111/1 Phase 11
SAREPTA [SRPT] Price: 28.30 52 Week HI: 53 Shares out: 41 Mill Book: 4.86 1 Phase 3/1Phase 11
That is true, but the stock has been grossly undervalued, the ASCO abstract in combination with video of Edith Perez and the near term initiation of Phase 11 in multiple indications [by end of 3rd quarter]
Has moved the stock, which is still very undervalued to it's peers at this point, listen to Glynn's conference call June 3rd that will give you the insight and update you need.
BLU
Completely agree RK, mentioned in the conference call June 3rd that in a matter of weeks the would put out full line of data, he also hinted at a new collaboration.
Also we only have 3 or 4 days to exercise the .50 warrants giving us the financing to fund FDA, and finish licencing agreement from Mayo.
Subsequential news could be Patent news, update on Polystart, Infectious Disease update, update on FDA application must also be close.
Hope that everyone is getting all the shares they need like RK says their are many catalyst's that will spur this higher in the short term, overall am pleased with how it has held up so far.
Seems like a lot of consolidation .75 area, if their is one fault in Tapimmune,it is the reluctance to keep shareholders updated. The positive on that, is all data has been peer reviewed and published to date.
Most of the hush hush can be attributed to the Mayo being so diligent in their process, which will only help us down the road, as it will be hard to dispute the work of Mayo, Edith Perez and Keith Knutson.
BLU
Article about Wilfred Jefferies the founder of TAP technology...just a little insight to where it all started.
Today, cancer is the No. 2
killer after heart disease. Within
about four years it will be No. 1,
killing upward of 730,000
Americans annually, according
to the National Cancer Institute.
It is against this dark statistic
that a discovery by a University
of British Columbia scientist
shines like the proverbial light
at the end of the tunnel. It turns
out that cancer tumors share a
BIOLOGY
Attacking Cancer
BY JIM WILSON
Jefferies’s cancer vaccine turns
the body’s natural defenses
against tumors.
common weak link: the inability
to tell the body’s immune system
that they need to be destroyed.
Wilfred Jefferies has found a way
to reverse that defect, and turn
the body’s natural defense into a
powerful ally.
Stimulating TAP
Think of a cell as a small engine.
It burns fuel and oxygen,
and gives off exhaust. Looking
at exhaust tells you a lot about
the condition of a vehicle’s engine.
The same holds true for a
cell. When something goes
wrong inside it, a cell sends out
the biochemical equivalent of a
puff of black smoke. Specialized
white blood cells tag the offenders.
Other cells—the immune
system’s hit men—move in for
the kill.
Among the white blood cells is
a group called T cells, so named
because they originate in the thymus
gland. “A subset of T cells
are responsible for killing virus infected
cells and cancer cells,”
Unless they are suffering from an
immune system disorder, most
people can rapidly produce massive
numbers of T cells to fight
invaders. The problem is that in
many cancer cells the ability to
emit a warning signal (“destroy
me”), in the form of a compound
called tumor antigen peptide, is
missing. “This hides the cancer
cells from the immune system,
and they grow into tumors that
eventually kill the person.”
Several years ago, Jefferies,
who is a professor of medical
genetics, microbiology and
immunology, tracked down the
root of the problem. Cancer cells
were producing a warning signal,
but it was not being pumped to
the surface. Closer investigation
revealed that the gene that told
the cell to produce a protein
called TAP (transporter associated
with antigen processing) was
disabled. “Loss of TAP expression
in tumors is highly correlated
with disease progression and
survival rates in humans,” Jefferies
says. “The 5-year survival
rate for patients whose tumors
[are] positive for the TAP protein
is nearly 90 percent. All of those
[negative for TAP] were dead
within four years.”
Jefferies reasoned that the problem
could be reversed by infecting
tumors with a virus that contained
a working copy of the
damaged gene. To test his theory,
he gave laboratory mice small-cell
lung cancer, followed by his TAP
technology cancer vaccine. Seventy
percent of the mice survived.
In the past, attempts to marshal
the immune system to fight
cancer have fallen short. Although
about 20 immune system-activating
drugs have been licensed
or are in clinical trials, none is
targeting as broad a spectrum
of cancers as TAP technology.
“TAP technology is a method of
restoring the ability of the body’s
immune system to recognize the
cancer cells as foreign, thereby
boosting the natural process for
destroying the cancerous cells,”
says Jefferies. He expects it also
would be used in conjunction
with existing cancer treatments,
such as chemotherapy.
Last year, Jefferies received a
U.S. patent for applying the TAP
technology to all solid tumors. In
addition to his university position,
he became chief scientific officer
for GeneMax of Blaine, Wash., a
company that will commercialize
the drug. Clinical trials should
be under way within about a
year. If it proves as effective in
humans as in lab animals, the
critical battle in the war on cancer
may have begun at last.
BLU
It’s a new day, and I’m one day wiser myself.
Let me first interject by saying, there are wiser men/woman on this board than I, secondly I would like to thank [in no particular order] Eagle 1, tootalljones, tpizzazz24, RK matters, Camoepaddler, itsthebox1, peterPanache, Sheezy, poor broke bloke, Rookie1 and any others I may have missed for your kind words.
I am by nature a someone who keeps mostly to himself, so my first foray into the world of message boards, has proven to be enlightening. You’re right many people have different/alternative agenda’s on the boards, so I will keep emotion out of the equation and simply try to help others with knowledge and facts as I uncover them.
You may always count that my agenda is to give honest, educated input when I can, having said that I am a fundamental guy, and until now have not really examined to any degree T/A because the variables in the market change moment to moment. And being more of a Buffett disciple [value investor] it does not come into play in my DD too often.
But as Cre8tivmynd, 123tom and others have pointed out, there is much to be learned/gained from both sides collaborating, there is no one clear cut path to success in the market, and all positive input is welcomed.
I do know my fundamentals inside and out, and can usually tell whether or not I would part with hard earned coin within ½ hour, then the real DD starts and continues every day to make sure the fundamentals do not change to any proportionate degree.
I will listen and try to examine T/a charts more, to give me a more rounded perspective, any help in that regard “is’ appreciated, one must walk through live with humility, honesty and strength...my Sensei instilled those qualities in me some 30 years ago...I digress.
Let’s work together to make TPIV as successful as we can in the coming months and years.
I’m “back Baby’ thanks mostly to your kind words.
One note in regards to the post by Mad Money Monkey, there were those of us that did not get wiped out on the 1/100 R/S, held 1.5 million shares at the split, was left with 15,000 then sold into the rise from opening around $2+ was luckily enough to sell around $4.17 on the rise to 7.
You are right almost everyone was wiped out, except those that bought too much too soon... so I or any other neither a “liar” or a “schmuck” as you posted...”fact”.
BLU
Think you may be right, pretty much the only message board I have posted on in all my investments, have been only trying to allow others insight that would benefit with my insight.
I had no other agenda, but think you are right, time to bid you Adiou...if anyone wishes leave private reply with your private email and I will respond in kind, and will help when I can...see you again at $10 plus.
Everyone in TPIV is a winner down the road.
GLTA
RKmatters, Definition of overbought...
o·ver·bought
/?ov?r'bôt/
1.
past and past participle of overbuy.
adjective
adjective: overbought; adjective: over-bought
1.
Stock Market
overvalued owing to excessive buying at unjustifiably high prices.
"a healthy correction to an overbought market"
Appreciate the message, don't have private reply.
BLU
The stock is at a very crucial stage right now, and as someone who paid the price to allow others such as yourself to even have a chance to trade TPIV as an on going entity.
We are the ones that believed and did the restructuring to allow you to benefit at our expense.
I and am very well versed on how stocks trade in most situations, as I have spelled out in previous posts.
"Grow Up" you say, I am a seasoned investors and was smart enough to have a 90% position at .14, this board is for pro TPIV investors, not people trying to prove how good the technical are.
This is the Bio tech arena it is Bust or Glory, most here are holding their share's, what possible motive would one have to make the comment the stock is "severely overbought" other than to make others second guess their buy.
Sensitive maybe but lost my mother to Ovarian Cancer so much more than money at stake for me.
BLU
A .5 cent decrease from your "severely overbought". You predicted at .81 "severely overbought", sp retraced twice to .75 for maybe 1 minute yesterday, then moved back to 95, today once again shorts trying to drive the price down.
Looks like once again to little or no avail
We have seen a four fold increase in sp over the past 3 weeks, a "severe overbought" would have driven the stock price back down to .50.
That is exactly the type of reasoning that makes others less educated in the stock sell and lose out on the big profits.
BLU
Bid and Ask have moved up here at 8:52 83.5 to 86 hope it's strength and not a head fake.
Today will really show at what level of strength .80 plus holds
Not selling even 1 share, as I now think that it could be in excess of $10 18/24 months.
Once again great to have such a knowledgeable and positive group to become millionaires with...lol.
BLU
Yes but most likely true all the same.
GLTA
BLU
Just wish to say, ash 111, RKmatters, Eagle 1, tootalljones and others thanks for the support along the way.
Hope you all have held on to the majority of your investment to date.
BLU
Many variables here, stock over the past 4 days has consolidated nicely on each .4, .5 cent move then has moved higher.
Management knows well that they have waited a long time to be in this position, it is going to be hard to get stock to drop appreciatively. I am sure that they have the game plan in place and seem to be executing it flawlessly at the moment.
$1.00 for 10 consecutive days and they will have raised another 5 to 10 million, along with the .50 they will have in 6/7 days.
Cash will be in place to execute the 2 to 4 dollar up-list, may see it happen before end of 3rd quarter now.
Getting into a position now that news of Fast Track, IND, Orphan Status, and start of PHASE 11 most likely will do it, still very undervalued here.
Cre8tivemnd...I won't mention your T/A extremely overbought thesis at .80 dropped to .75 for 7 minutes and only traded their for 30 seconds .
Hang on GLTA
BLU
Actually here is the comment in question, as your comment is directed to me
Quote: I expect pps to be volatile tomorrow. Perhaps opening higher, then selling off throughout the morning. Stock is extremely overbought short-term. Could come back in the afternoon. I only see this as a very short-term correction, before heading higher toward that Dollar area....Fwiw.
Simply took exception to the comment "Stock is "extremely" overbought short term, that coming from someone who's alias was born 05/06/15...simply not the truth.
Those of us that have followed, participated and understand both management and science, only input educated DD on Tapimmunes's potential moving forward.
How can a stock that is severely undervalued be severely overbought simply because it has moved .40 .50 cents?
If you had done your DD you would know that the stock is just catching up after outstanding data, and a number of other strong catalyst's.
I have been spot on in my posts to date, because I am well versed in TPIV, years worth of hard work.,
I post here solely to help others understand what has transpired over the last few years, Tapimmune's past has been a complicated one but looks like the pieces are now falling into place.
May their be some consolidation into the +.70 I agree maybe, but the rise back up most likely will be swift, simply don't want those less knowledgeable to make a mistake for a few cents.
Any news despite how small will propel this over $1.00 and maybe will go without news.
Once again GLTA, everyone trades with their own agenda.
BLu
T/A hasn't worked on this stock so far, TPIV is a fundamental driven company, everyone was saying for the past 2 weeks that it would get stuck on resistance at .40 and then again at .60...blew right through those indicators.
TPIV was and is a longer term hold for me, but I have made 5 times my investment over the past month, did not sell and buy on small dips, and in doing so still hold my close to 200,000 shares but worth much more today than last week.
Everyone chooses to "play" the market in their own way, I am simply trying to help those understand one stock "TPIV" of which I am well versed.
You don't see me hyping 2, 3 or more stocks, only trying to help those in Tapimmune, if it dips a few cents tomorrow, or moves forward a million variables in the market as a whole will determine that move.
Starting with watching the US stock futures and world events, but overbought I think the market is simply catching up and still not nearly there.
If it does retract, which may very well be a possibility, gives a buying opportunity for others, but I believe that the game plan is in effect, and traders will/have already misjudged TPIV's performance, trying to make a few cents, trying to curtail what may be a locomotive.
Understanding the rationale of management is a big part of where this goes, those that have not followed the company for quite some time...are at a disadvantage.
T/A does not factor in day to day world events, which override even the best fundamentals, the market as a whole has almost no rationale.
We are on the same page, we believe in the company/science a few cent's, here or there are of no concern at this point. Those that have sold for what they thought was a great return last week have missed out on a much nicer move.
Some stocks are more tradable, and some have catalyst's that make trading them all the time less productive, I think TPIV is just that at this crucial stage.
Once again GLTA
BLU
How do you possibly say that it is overbought lol at .80?
It has been consolidating/selling buying ratio as it has been moving up, still very undervalued at this price.
Remember it has ben undervalued for so long, news should be out soon with full data results...have watched almost every trade for past 4 days consolidation up, consolidation up.
We are still the lowest price in the space by a large margin, with the science.
I would think any consolidation will be minor, think game is on to get cash and price into NASDAQ territory I believe going into start of PHASE 11.
BLU
Burrhead1; based on 2 things I have a number in my head of minimum of $10 first of which is a fair value based on outstanding shares with in 18/24 month's.
Believe there will be in the ballpark of 80 to 100 million shares out within that timeframe, don't think they'll have to issue more. As most companies when entering PHASE 11 [if drug/science is good]garner significant interest from Big Pharma.
Last year saw two acquisitions/buyouts over a billion so hence the $10 target, but KITE,JUNO have traded as high as $60 to $90 per share already with comparative science.
So potential could be much, much higher I would think that after all the years and hardships Tapimmune has overcome, I have been through it all with them, that they could hold out for $15/$20.
A big definer will be every 6 month's of non recurrence of cancer.
Remember Edith Perez did the Herceptin 6 billion year and TPIV science so far exceeds that by at least double amount of people that can be treated.
Anyway you slice this it may be a monster...time to recurrence I think will be the key.
No one is even talking about their Infectious Disease arm a completely separate entity...would love a spin off of that to shareholders.
BLU
BLU
36 trading years for me "tootalljones", and I believe this may be the best investment I have been involved in.
Have had other's that have been 10 baggers or more...DD is the key to finding great investments.
Time will tell, haven't sold a share and don't plan to.
BLU
Understand, I have been in Tapimmune for 5 years so very well versed, they have the potential to be in the league of KITE, JUNO IMMU and many others.
This price is still ludicrously low, up-listing may very well garner prices such as above mentioned.
BLU
Charting this stock has not and will not work, as I mentioned when it was in the .30's and people said that their was heavy resistance at 3 different inflection points that we have already pushed through.
Do your DD way to many catalyst's in the near term to chart, resistance will be crashed again, like they have already. Even now people will be starting to entertain the vision of the up-list.
Good luck trading this, many who thought they could, are most likely now wishing they had held their full position, even at this point in time the stock should be $2 or $3 ahead of the PHASE 11 news.
BLu
Just remember; When stock stays above .50, next 7 days TPIV can exercise the warrants 5 million, then when it hits $1.00 for 10 days another 5 to 10 million.
It looks like the timeline may fall right into the FDA and initiation of PHASE 11 trial, if they get either of the Fast Track, Orphan or IND watch out. They will have the cash position in place, and the for-mentioned news will most assuredly move the price past the $2 and into the $4 range.
Then any speculation of the NASDAQ up-list, will bring in the Funds, Brokerages for client accounts the list of catalyst's goes on and on, if time to recurrence is still very favorable into PHASE 11 they will have the best science of anyone...sky is the limit.
Then it could be matched against the like's of KITE, IMMU, JUNO buyout may be imminent, so many catalyst's so little time...lol.
Just my take.
BLU
Moonistea; How are you shocked, the way you are talking you are surprised that TPIV which has been completely ignored for the past 18 month's in the investment community, while other companies with science/technologies far less superior than them have garnered the spotlights...cases in point
RNN, GALE even the high flyers like KITE, up almost 7 dollars today on nothing, these companies are not much farther along, and science's are inferior too Tapimmune's.
The stock is still so very undervalued at this point, when Edith Perez who worked on the Herceptin trials for Roche, came out and said that now she believes they may be a vaccine for TNBC, not too mention HER2/nue, Ovarian and possibly many others. In conjunction with DART taking a massive position what did you expect?
DART"S participation seems to have solidified their path to getting up-listed as soon as possible, reducing the warrant prices has simply [as GLYNN has stated] expedited that process.
They also needed FDA approval cash, money for licencing the technologies from MAYO, patent protection fees and other entry into PHASE 11 cost's. In order to get up-listed they have to show a substantial cash position and are very near that now, .50 warrants exercisable in 8 days if price stays above .50.
They have in the past two month's put together all the pieces to make the up-listing possible by year end [possibly sooner], the stock should "never" have been as low as it was, and I believe that there will be little retraction in the share price moving forward.
No amount of bashing from anyone is going to change that now, you and others know that the share price should be north of $2 as we speak. Within 3 month's they most likely will have PHASE 11 trials in 2 or 3 billion dollar markets in indications that have no viable treatment.
.60 this is a joke, it is amusing to listen to people who have not done thorough DD, that this company now does not have all the pieces to easily be not only in the arena of the KITE'S and JUNO'S but to be the leader in this space.
As I have mentioned before, the low cost of the treatment is a game changer, and the science is a life saver, science may be better than Herceptin 7 billion a year 15/20 % versus ours 50% plus.
Each new piece of news will drive this higher, the days of OTC manipulation are nearing an end, those waiting for .35/.40 prices again have missed the boat.
Who here dispute's the MAYO, Edith Perez, Keith Knutson, and DART
not me...
BLU
TY; No day job, "freedom 55" don't dabble in OTC's too much but TPIV was a different matter knew from the outset that this had the possibility to be a monster.
Usually concentrate on very undervalued or beaten down stocks with substantial upside, that have great fundamentals.
Thanks, am long term and have a substantial position in TPIV no day trader here, Canada's Tax Laws to harsh on holdings 1 year and a day or under.
Thanks TUITUI.
BLU
Question; Does anyone have level 11 with iHUb and how do they like it, apparently $33 per month.
BLu
RiskyChick: They have already done a 1/100 R/S a year ago, I am thinking that there is a small chance at this point. As they were offering approx. 70 million warrants at $1.25 and under I briefly entertained that premise also.
But if the stock stays above .50 for the next 8 trading days, they will trigger a minimum 5 million financing, allowing them to solidify licencing deals in place from MAYO, then activated warrants all under a dollar brings in another 5 to 10 mill.
Since DART has increased his position, I now think that he will dry up his selling after the .50 are exercised, when that happens very small float. And as the price stands today, to buy 100,000 shares will cost someone $60,000, that makes the price rise more dramatically and quicker.
We are also forgetting about their INFECTIOUS DISEASE platform which there could be a possibility that they could make a separate subsidiary. Or even spin it off as a separate company. I was involved with another company that did just that.
My thinking is that DART is going to get this up-listed sooner than later, then we have the funds, brokerage's entering the picture which most likely will appreciate the price significantly.
Hope that helps.
BLU
At the risk of offending, jbem777...TPIV was not unknown to some of us, I discovered TPIV from my DD of Wilfred Jefferies work at UBC [Founder of TAP technology],was involved in the .14 Bridge financing, and have purchased stock periodically over time pre .20.
I must admit I am somewhat perplexed at your rationale to trade in a .60 stock for a $7 stock that cannot begin to compare to the [near term] potential of Tapimmune.
Just trying to give the ones already in TPIV an educated insight, there is no other agenda but to educate, from someone who has been in the stock for many years.
Reality is, TPIV may be one of the biggest gainers, that any of us will have the pleasure of being involved in, flipping is great but time has proven out that long term holds on stocks such as TPIV far out ways buying/selling for short gains and missing out on the big move. We are all aware a double from here is nothing.
I have reiterated before that I am a long term, value driven investor, don't wish to offend, once again everyone makes money their own way. Make a million or more off TPIV in 18/24 months seems like a sound investment to me.
Once again GLTA, any questions that I can answer I will gladly try.
What's the deal moneypenny, already telling people to get out when there are so many catalyst's in the near future, why are you wanting others to sell knowing what is coming.
Did my DD on TNXP may be nice but the move on TPIV will far out way TNXP, you really think that TNXP is going to double before TPIV? No multi billion dollar markets there!
TPIV should already be minimum a few bucks the rise to .60 is nothing, now the buying really starts, sorry to say but if holds for 10 days, they will be announcing exercising of .50 warrants, that's five million.
And Glynn has hinted twice now that they have, or are close to a new partner so many catalyst's why would others wish to sell for pocket change and miss the big move...buying at tremendous stock at .60 or less on pull back, or buying at mediocre stock at $7?